ByTrending Posts
Can Unnatural Products and Novartis Unlock “Undruggable” Cardiovascular…
Santa Cruz, Calif., February, 2026 — Unnatural Products, Inc. (UNP) today announced a research collaboration and licensing agreement…
Can Foundation Medicine and Manifold Redefine Precision Oncology…
Are Foundation Medicine and Manifold Signaling the Next Evolution of AI-Integrated Oncology Intelligence? In a strategic move to…
Can Generate Biomedicines—Backed by Amgen and Novartis—Redefine Biologics…
Generate Biomedicines, Amgen and Novartis Signal Capital-Market Validation for AI-Driven Biologics Innovation The AI drug discovery sector is…
Can Insilico Medicine and China Medical System Accelerate…
Executive SummaryIn a strategic expansion of their collaboration in February 2026, Insilico Medicine and China Medical System Holdings…
Can Angelini’s $120M AI Alliance with Quiver Bioscience…
Executive SummaryIn a strategic push to strengthen its neuroscience pipeline, Angelini Pharma has entered a multiyear collaboration with…
Is Takeda’s $1.7B Bet on Iambic Therapeutics the…
Executive SummaryIn one of the largest AI-driven drug discovery collaborations to date, Takeda Pharmaceutical has entered a multiyear…
Can Hippocratic AI’s Acquisition of Grove AI Trigger…
Executive SummaryAt the 2026 JPM Healthcare Conference in San Francisco, Hippocratic AI announced the acquisition of Grove AI,…
Innovent and Eli Lilly Expand Strategic Alliance to…
Shanghai, China – February, 2026 – Innovent Biologics Inc today announced a new strategic collaboration with Eli Lilly…
Eli Lilly to Acquire Orna Therapeutics in Deal…
Indianapolis, IN – February 9, 2026 – Eli Lilly and Company today announced it has entered into a…
Trending Posts
Latest Stories
Is Hong Kong Becoming Asia’s AI–Biopharma Hub?
Hong Kong is emerging as a key AI‑biopharma hub, with recent deals like Earendil Labs’…
Is Insilico’s AI Drug Engine “Einstein” Turning China into the Global AI–Pharma Hub?
Insilico Medicine’s AI‑driven drug discovery platform, Pharma.AI “Einstein,” is scaling fast in China, with a…
Biotech Licensing Soars to $137B in 2025 – China Now Leads the Licensing Race
The global biotech licensing market hit a record $137 billion in 2025, and 2026 is…
China Dominates 70% of Global AI Drug Patents: ADC/Bispecifics Surge or Innovation Bubble?
China Leads 70% of Global AI Drug Patents: Simple Strategic Snapshot China now holds 70%…
Gallery
